Tobramycin dry-powder inhalation - Novartis

Drug Profile

Tobramycin dry-powder inhalation - Novartis

Alternative Names: TBM 100; TIP; TOBI Podhaler; TOBI-TIP; Tobramycin inhalation powder-Novartis

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Nektar Therapeutics
  • Developer Novartis
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Phase II Bronchiectasis

Most Recent Events

  • 01 Feb 2017 Phase-II clinical trials in Bronchiectasis (Adjunctive treatment) in Italy, Spain, Germany, Ireland, United Kingdom (Inhalation) (NCT02712983) (EudraCT2015-003040-39)
  • 15 Mar 2016 Biomarkers information updated
  • 14 Mar 2016 Novartis plans a phase II trial for Bronchiectasis (Adjunctive treatment) in United Kingdom (Inhalation) (NCT02712983)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top